ImpediMed
Australia - PinkenbaBiotechnology
Focus: ImpediMed is a medical device biotech specializing in bioimpedance spectroscopy technology for non-invasive clinical assessment and monitoring of tissue composition and fluid status. The company operates from Australia with a focused pipeline in heart failure, lymphedema, and chronic kidney failure.
Profile data last refreshed 3h ago · AI intelligence enriched 3w ago
Open Jobs
0
About ImpediMed
AI assessmentNot HiringNo open roles listed right now. Follow ImpediMed to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from ImpediMed's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
10 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
The Equivalency of the Imp SFB7+ (L-Dex U400) With the Imp XCA Device
LymphedemaClinical Trials (1)
NCT00766935The Equivalency of the Imp SFB7+ (L-Dex U400) With the Imp XCA Device
N/AHelp build intelligence for ImpediMed
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.